Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 106, Issue 10, Pages 1583-1586
Publisher
Springer Nature
Online
2012-04-18
DOI
10.1038/bjc.2012.144
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mitogen-activated Protein Kinase Kinase 1 (MEK1) Stabilizes MyoD through Direct Phosphorylation at Tyrosine 156 During Myogenic Differentiation
- (2011) Chulman Jo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Definition and classification of cancer cachexia: an international consensus
- (2011) Kenneth Fearon et al. LANCET ONCOLOGY
- Body composition in patients with non−small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis
- (2010) Vickie E Baracos et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies
- (2010) Shontelle Dodson et al. Annual Review of Medicine
- Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
- (2010) Xiaolan Zhou et al. CELL
- Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study
- (2010) Sami Antoun et al. JOURNAL OF CLINICAL ONCOLOGY
- Powerful signals for weak muscles
- (2009) Amarjit Saini et al. AGEING RESEARCH REVIEWS
- A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands
- (2009) Jessica R Lieffers et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
- (2009) C. M.M. Prado et al. CLINICAL CANCER RESEARCH
- Update on emerging drugs for cancer cachexia
- (2009) Kate T Murphy et al. EXPERT OPINION ON EMERGING DRUGS
- The role of cytokines in cancer cachexia
- (2009) Josep M Argilés et al. Current Opinion in Supportive and Palliative Care
- A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care
- (2008) Marina Mourtzakis et al. Applied Physiology Nutrition and Metabolism
- Cholangiocarcinoma
- (2008) Stefania Mosconi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Inflammatory burden and amino acid metabolism in cancer cachexia
- (2008) William J Durham et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study
- (2008) Carla MM Prado et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now